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Abstract
Background: Ambrisentan is a selective endothelin receptor antagonist used for the treatment of pulmonary
arterial hypertension (PAH). Little is known about ambrisentan removal by hemodialysis in patients with end-stage
renal disease (ESRD).
Case presentation: A 53-year-old woman with HIV/hepatitis C virus (HCV) co-infection, PAH and ESRD on regular
hemodialyis was admitted in our hospital due to refractory heart failure while on treatment with bosentan (125 mg
twice daily) and tadalafil (20 mg once daily) for PAH and antiretroviral treatment (cART) including darunavir/
cobicistat (800/150 mg once daily). Excessive exposure to bosentan due to drug interactions between bosentan and
darunavir/cobicistat was suspected. Bosentan was replaced by ambrisentan, with progressive improvement in her
clinical condition. Pre- and postdialyzer cocentrations of ambrisentan in plasma were determined and hemodialysis
extraction ratio for ambrisentan was 2%.
Conclusions: Our results suggest that hemodialysis results in minimal ambrisentan removal, and therefore no
specific ambrisentan dosage adjustment seems to be required in ESRD patients undergoing hemodialysis.
Keywords: Ambrisentan, Hemodialysis, Pulmonary arterial hypertension, HIV-infection, Drug interactions
Background
The life expectancy of people living with HIV has shown
significant improvement in recent decades, largely due to
the widespread use of combined antiretroviral therapy
(cART). However, this has been followed by an increase in
the prevalence of non-AIDS-defining co-morbidities, in-
cluding pulmonary arterial hypertension (PAH) and
chronic kidney disease [1, 2]. The prevalence of PAH in
the HIV population is approximately 0.5%, with a little
variation since the introduction of cART. Nevertheless,
the number of HIV-infected patients with end-stage renal
disease (ESRD) requiring renal replacement therapy has
increased.
Defining optimal dosing of many drugs in patients on
hemodialysis may be difficult. Drug removal by
hemodialysis is an essential factor in determining differ-
ent dosing regimens. However, the pharmacokinetics of
many drugs in patients on hemodialysis has been poorly
studied, and information about their hemodialyzability
remains scant [3–5]. In addition, HIV patients with PAH
or ESRD are frequently affected by other co-morbidities
that require specific therapies. These patients often
receive many different drugs (polypharmacy), with a
potential risk for drug-drug interactions among them [6,
7]. Here we report a clinical case involving an HIV-1-
infected patient with severe PAH and ESRD on
hemodialysis who was treated with ambrisentan with the
intention to avoid drug interactions between bosentan
and cART. Ambrisentan is a selective endothelin-A re-
ceptor antagonist, which is approved for the treatment
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of PAH [8, 9]. However, despite its better pharmacoki-
netic profile in comparison to bosentan, no data on
ambrisentan pharmacokinetics in hemodialysis patients
were available, so we evaluated the effect of hemodialysis
on ambrisentan concentrations.
Case presentation
The patient in this clinical case was a 53-year-old
woman who was admitted to our hospital with severe
respiratory failure. She had been diagnosed with HIV/
hepatitis C virus (HCV) co-infection in 2000 as well as
with PAH in 2002. In addition, she had ESRD and had
been undergoing high-flux hemodialysis sessions since
2014 (vascular access: venous-arterial fistula; dialyzer:
Revaclear® 400, capillary 101 dialyzer, membrane area
1.8 m2; Bicart® Gambro bicarbonate cartridge; blood
flow: 350 mL/min; dialysate flow: 500 mL/min). The pa-
tient was undergoing 3 dialysis sessions per week and
each session lasted approximately 4 h.
In January 2018, the patient was receiving cART with
lopinavir/ritonavir (400/100 mg twice daily) plus ralte-
gravir (400 mg twice daily), as well as bosentan (125 mg
twice daily) plus tadalafil (20 mg once daily) for PAH. At
that time, treatment with glecaprevir/pibrentasvir was
indicated for HCV. To avoid drug interactions with
HCV drugs, cART was switched to raltegravir (400 mg
twice daily) plus rilpivirine (25 mg once daily), and
bosentan and tadalafil were temporarily discontinued. In
April 2018, after completing 8 weeks of HCV treatment,
bosentan and tadalafil were reintroduced at the same
doses as before HCV treatment, and rilpivirine was re-
placed by darunavir/cobicistat (800/150 mg once daily).
From April 2018 to September 2018 the patient had
several episodes of congestive heart failure, which were
satisfactory managed with medical treatment. Neverthe-
less, in September 2018 the patient presented with se-
vere respiratory failure and clinical signs compatible
with decompensated heart failure, and she had to be
hospitalized. On her admission, the patient underwent
daily hemodialysis sessions, and the negative fluid bal-
ance in each session was increased. However, the re-
sponse to hemodialysis was poorer than expected,
suggesting additional determinants of her clinical situ-
ation. In addition, during the admission, virologic failure
was evidenced by an HIV-1 RNA load in plasma of 5424
copies/mL, with HIV evolution and development of new
drug resistance mutations in the integrase gene (N155H)
not present in previous genotypes. After ruling out other
conditions, bosentan toxicity—probably because exces-
sive exposure to bosentan due to drug interactions be-
tween bosentan and darunavir/cobicistat was considered.
Bosentan was therefore replaced by ambrisentan with
the intention of avoiding drug-drug interactions with
cART. Additionally, cART was optimized, and the
regimen was changed to darunavir/ritonavir (800/100
mg once daily) plus etravirine (200 mg twice daily) and
dolutegravir (50 mg twice daily). Thereafter, the patient
experienced progressive improvement in her clinical
condition, HIV RNA in plasma was re-suppressed (< 40
copies/ml), and she was finally discharged to resume her
usual hemodialysis program (3 sessions per week).
To evaluate the effect of hemodialysis on ambrisentan
plasma concentrations, paired samples of blood entering
(‘in’) and leaving (‘out’) the dialyzer and of the resulting
dialysate were collected during one dialysis session.
Blood samples were collected into heparin-lithium-
containing 4-ml tubes 12.2 h after last ambrisentan dose.
Plasma was isolated by centrifugation (3200 g for 15
min), and stored at − 80 °C until analysis. Dialysate (20
ml) was directly collected from the dialysate port of the
dialyzer. Ambrisentan concentrations in both plasma
and dialysate were determined using high-performance
liquid chromatography coupled with tandem mass spec-
trometry (LC-MS/MS) using a validated method [10],
and the hemodialysis extraction ratio (ER) for ambrisen-
tan was calculated following standard procedures [5].
The patient gave and signed an informed consent before
sampling took place.
The effect of hemodialysis on ambrisentan concentra-
tions was evaluated during one hemodialysis session.
Pre- and postdialyzer total ambrisentan concentrations
were 42.8 ng/mL and 42.5 ng/mL, respectively, with neg-
ligible ambrisentan concentrations in dialysate (3.92 ng/
mL). The hemodialysis extraction ratio was only 2.0%.
At the end of the dialysis session (26.3 h after dosing),
total ambrisentan concentrations in plasma were 35.6
ng/ml.
Discussion and conclusions
The small differences between plasma ambrisentan concen-
trations going in and coming out of the dialyzer, together
with barely noticeable ambrisentan concentrations in di-
alysate in this patient, suggest a minimal removal of ambri-
sentan by hemodialysis in patients with ESRD. This finding
is consistent with the physiochemical characteristics of
ambrisentan, which is 99% bound to plasma proteins, and
is minimally eliminated by the kidneys, with only 3% of its
dose being excreted unchanged into urine [8].
Besides the effect of hemodialysis on ambrisentan con-
centrations, the clinical case presented here highlights
the complexity of drug-drug interactions affecting HIV-
infected patients. In this case, mutual interactions be-
tween bosentan and cART were suspected. The patient
had clinical signs of fluid retention associated with
bosentan toxicity, which was presumably the result of
excessive bosentan concentrations due to potent cyto-
chrome P450 3A4 (CYP3A4) inhibition by cobicistat. Al-
though no specific studies have evaluated the effect of
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cobicistat on bosentan pharmacokinetics, data with lopi-
navir/ritonavir have shown a rather substantial > 5-fold
increase in bosentan exposure [11]. In the other direc-
tion, bosentan induces CYP3A4 activity [12], which is
the main metabolic pathway for both darunavir and
cobicistat. Previous studies have shown a decline in cobici-
stat exposure, and consequently inappropriately low
darunavir concentrations, when darunavir/cobicistat is
combined with the CYP3A4 inducers [13]. Consequently,
combining bosentan with darunavir/cobicistat plus raltegra-
vir could have resulted in functional monotherapy with ral-
tegravir, leading to the virological failure and the
development of new resistance mutations observed in this
patient. Unfortunately, although it seems the most plausible
hypothesis, no plasma samples to determine bosentan and
antiretrovirals concentrations were available. Nevertheless,
progressive improvement in the clinical condition of the pa-
tient along with re-suppression of HIV RNA after switching
to ambrisentan and ART adjustment is concordant with
our theory.
Ambrisentan is a selective endothelin-A receptor antagonist
with proven efficacy and safety in the treatment of PAH [8].
In contrast to bosentan, ambrisentan is only a minor sub-
strate of CYP3A4 and its elimination is mainly mediated by
glucuronidation via several uridine-glucuronosyltransferase
(UGT) isozymes [8]. Thus, the effect of potent CYP3A4 in-
hibitors on ambrisentan pharmacokinetics is much less com-
pared to bosentan, and ambrisentan may be safely used in
this scenario, as observed in our patient. Moreover, ambrisen-
tan does not have any significant effect on the activity of
UGT or cytochrome P450 isozymes or drug transporters, lim-
iting the possibility of drug-drug interactions. It is noteworthy
that ambrisentan concentrations at the end of the dialysis ses-
sion were in the same range as those described in healthy vol-
unteers receiving regular doses [14, 15], suggesting the
absence of a need for dose adjustment in patients with ESRD.
Based on the minimal extraction ratio of ambrisentan
by hemodialysis observed in our patient, no ambrisentan
dose adjustment seems to be necessary in patients with
PAH and ESRD undergoing hemodialysis. However, fur-
ther investigations in this topic are recommendable. HIV-
infected patients receiving polypharmacy may be affected
by complex drug-drug interactions that require appropri-
ate management, ideally by multidisciplinary teams with
fluid communication among different prescribers.
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